Repertoire Launches To Turn Immune System Insights Into T-Cell Therapies, Vaccines

 
• By Mandy Jackson

Flagship Pioneering combined Torque Therapeutics and Cogen Immune Medicines, which have raised more than $220m, into Repertoire Immune Medicines with an autologous T-cell therapy being studied in a Phase I trial.

T cell lymphocyte with receptors to kill cancer cell in cancer immunotherapy 3D render
Repertoire's first clinical trial is for an autologous T-cell therapy • Source: Shutterstock

More from R&D

More from Scrip